Industry Experts

Dr. Catherine Campbell is a seasoned regulatory affairs leader with over 16 years of experience in the biotechnology industry, currently serving as Vice President of Regulatory Affairs, Quality and GxP Compliance at 4D Molecular Therapeutics. She brings deep expertise across the regulatory spectrum, including BLAs, MAAs, JNDAs, CTAs, INDs, and IMPDs, with hands-on experience spanning cGCP, cGMP, and CMC for small molecules, biologics, gene therapies, combination products, and orphan indications.

Catherine’s career includes leadership roles at both 4D Molecular Therapeutics and BioMarin Pharmaceutical Inc., where she supported regulatory strategies and submissions across global markets, including the US, EU, UK, Canada, Japan, Russia, Ukraine, and Latin America.

She holds a Ph.D. in Neuroscience from the University of British Columbia (2001–2006), and leverages her scientific research foundation to drive regulatory excellence in central nervous system diseases, lysosomal storage disorders, retinal disorders, and other rare diseases.